Magnetic Resonance Imaging Guided Gynecologic Brachytherapy
Cervix Neoplasms, Uterine Neoplasms, Vaginal Neoplasms
About this trial
This is an interventional treatment trial for Cervix Neoplasms focused on measuring MRI, Brachytherapy, Carcinoma, Cervix, Uterus, Vagina, Vulva, Carcinoma of the cervix, Carcinoma of the uterus, Carcinoma of the vagina, Carcinoma of the vulva
Eligibility Criteria
Inclusion Criteria: Histologic documentation of carcinoma. Carcinoma of the cervix: Stage IIIB, IVA or vaginal recurrence Carcinoma of the cervix: Stage IB, IIA, IIB or IIIA with obliteration of the cervical os (tandem and ovoid implant not feasible) Carcinoma of the uterus: Stage IIIB (vaginal involvement) or vaginal recurrence Carcinoma of the vagina: Stage II, III, IVA or vaginal recurrence Carcinoma of the vulva: T3 (vaginal extension) or T4 (inoperable - any N stage), or vaginal recurrence MRI and CT of the pelvis within 2 months before registration ECOG performance status of < 2 Age > 18 Signed informed consent No metallic objects or pacemakers in the patient Negative pregnancy test for those of child-bearing potential Patients who have received prior radiation or chemotherapy may be enrolled on this study. Documented complete blood count (CBC) with hematocrit (Hct)>30, absolute neutrophil count (ANC)>500, platelet (Plt) >40 Exclusion Criteria: Patients with distant metastasis. Baseline studies not obtained. Patients who are pregnant or lactating. Significant history of cardiovascular disease.